^
Association details:
| Biomarker: | SYNE1 mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
Published date:
10/08/2020
Excerpt:
To evaluate the ability of SYNE1 mutation to serve as a biomarker predictive of the clinical response to ICB therapy, we analyzed datasets from patients with stage 4 ccRCC using the TIDE algorithm. The results showed that the mt group was associated with lower TIDE scores, indicating a stronger response to ICB therapy....These findings suggest SYNE1 mutations may play a role in ICB therapy in ccRCC.
DOI:
10.18632/aging.103781
